Cite
HARVARD Citation
Amin, A. et al. (2015). Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. Journal for immunotherapy of cancer. 3 (1), pp. 1-13. [Online].